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Summary This paper examines the expression of fibroblast growth factor 2 (FGF-2) in the malignant human breast. Semiquantitative reverse
transcriptase-polymerase chain reaction (RT-PCR) was used to assess the level of expression of FGF-2 in a series of 51 patients clinically
followed up for a median of 84 months (Luqmani et al, 1992). Immunohistochemistry and Western blotting were used to show that the level of
FGF-2 in breast tissues correlated with the amount of FGF-2 mRNA. FGF-2 was present in both malignant and non-malignant breast,
although less was expressed in malignant tissues as determined by all three methods. Immunohistochemistry on frozen sections of breast
tissue showed expression of FGF-2 in myoepithelial and epithelial cells in non-malignant samples and generally lower or undetectable levels
of staining in malignant epithelial cells. The results obtained by immunohistochemistry correlated well with RT-PCR data showing similar
levels of FGF-2 and FGF-2 mRNA expression in samples. No correlation was found between FGF-2 mRNA expression and T stage, nodal
status or oestrogen receptor status. However, Kaplan-Meier survival plots show that higher levels of FGF-2 are associated with improved
overall and disease-free survival. We suggest that FGF-2 expression may have value as a prognostic indicator in breast cancer.
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The fibroblast growth factors (FGFs) form a family of nine identi-
fied growth-regulatory proteins that share 35-50% overall
homology and induce proliferation and differentiation of a wide
range of cells of epithelial, mesodermal and neuroectodermal
origin (Gospodarowicz et al, 1987; Basilico and Moscatelli, 1992;
Klagsbrun, 1989). All except FGF-l and FGF-2 are synthesized
with an N-terminal hydrophobic signal sequence, enabling the
classical mechanism of secretion from cells (Abraham et al, 1986;
Jaye et al, 1986). Release ofFGF-1 and FGF-2 may occur through
leakage from damaged cells or from viable cells through a novel
mechanism (Mignatti et al, 1992). FGF-2 has diverse biological
functions, which include involvement in cellular growth, differen-
tiation, embryogenesis, wound healing, plasminogen activator
synthesis, invasion and angiogenesis (Montesano et al, 1986;
Gospodarowicz et al, 1987; Sato and Rifkin, 1988; Klagsbrun,
1989; Tsuboi and Rifkin, 1990; Tsuboi et al, 1990). Several of
these functions could influence the progression of cancer by
encouraging cell growth or metastasis, and FGFs have conse-
quently been studied in several cancers.
FGF-2 has been detected in a variety of human cancers,
including colonic adenocarcinoma (New and Yeoman, 1992),
bladder cancer (Allen and Maher, 1993), rhabdomyosarcoma
(Schweigerer et al, 1987), ovarian cancer (Crickard et al, 1994),
pancreatic carcinoma (Leung et al, 1994), renal cell carcinoma
(Emoto et al, 1994) and oesophageal carcinoma (lida et al, 1994).
Studies of human breast have shown high levels ofFGF-2 mRNA
in non-malignant breast, with malignant transformation of epithe-
lial cells leading to reduced expression (Luqmani et al, 1992;
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Anandappa et al, 1994). However, both studies showed that about
one in four cancers expressed FGF-2 mRNA at levels similar to
those found in the benign tissue. A similar pattern is seen for
FGF-1 expression in the breast, as lower amounts of FGF-1 and
FGF-1 mRNA were found in malignant breast tissue than in non-
malignant breast tissue (Bansal et al, 1995). The principal source
of FGF-2 in the breast appears to be myoepithelial cells. FGF-2
mRNA has been detected in both epithelial and myoepithelial
breast cells, with the latter expressing higher levels (Ke et al,
1993). Immunohistochemical studies using paraffin sections have
shown that FGF-2 localizes to myoepithelial cells and the base-
ment membrane in benign breast biopsies and intraduct carci-
nomas (Gomm et al, 1991).
The cellular response to FGF-2 is mediated through the forma-
tion of a trimolecular complex composed of FGF-2, one of the
high-affinity FGF receptors (FGFR) and an extracellular matrix or
cell-surface heparan sulphate proteoglycan (Yayon et al, 1991). A
family of four high-affinity receptors encoded by separate genes
has been identified, and the complexity ofthis family is enhanced
by an array of spliced variants (Jaye et al, 1992). The principal
high-affinity receptors for FGF-2 appear to be FGFR-1 and one of
the splice variants of FGFR-2 (FGFR-2-IIIC) (Mansukhani et al,
1992; Werner et al, 1992). FGFR-3 and FGFR-4 bind to FGF-2
with lower affinity (Ron et al, 1993; Chellaiah et al, 1994). Both
FGFR-1 and the IlIc variant of FGFR-2 are present in breast
cancers (Luqmani et al, 1992; Penault-Llorca et al, 1995). The
relative level of the beta (2-immunoglobulin-like domain) form
compared with the alpha (3-immunoglobulin-like domain) form of
FGFR-1 is higher in malignant breast biopsies (Luqmani et al,
1995). The beta form of FGFR-1 has been reported to have a
higher affinity for FGF-2, indicating that breast cancer cells may
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bind efficiently to any available FGF ligand (Shi et al, 1993).
Amplification of the FGFR-1 and FGFR-2 genes has been
observed in 12.7% and 11.5% of 387 breast cancers respectively
(Adnane et al, 1991).
Several studies mentioned above have shown thatFGF-2 mRNA
is present in generally lower quantities in human breast cancer
than in non-malignant tissue. We have extended these studies and
report here that FGF-2 protein reflects this trend, with generally
lower amounts being detectable in malignant tissues. We have also
used previously obtained data on FGF-2 mRNA levels in breast
cancers to investigate whether FGF-2 expression may be a prog-
nostic indicator. We find that low expression of FGF-2 mRNA
correlates with decreased disease-free and overall survival.
MATERIALS AND METHODS
Patients and tissue samples
Table 1 shows the clinical details ofthe 59 patients whose tumours
were used in this study. Malignant breast tissues were obtained
between 1980 and 1990 frompatients attending the breast clinic at
St George's and Charing Cross Hospitals, London, UK. They were
immediately snap frozen in liquid nitrogen after surgery.
100%) for 5 min. Sections were washed in PBS (pH 7.2) and
blockedforendogenousbiotin, following theprotocol includedwith
a biotin blocking kit (Vector Labs). After three further washes in
PBS, sections were preincubated with normal goat serum (15% in
PBS with 5% bovine serum albumin) for 30 min at room tempera-
ture. After discarding the preincubation buffer, sections were incu-
bated ovemight at 4°C with a rabbit polyclonal antibody to FGF-2
(0.5 jg ml-') (a kind gift from Dr A Baird) or non-immune rabbit
IgG at an equivalent concentration, diluted in PBS containing 15%
goat serum and 5% bovine serum albumin (BSA). As a further
control, FGF-2 was used as an antigenblock. FGF-2 (5 jigml-') was
preincubated with rabbit polyclonal antibody to FGF-2 (0.25 jg
ml-') for 16hat4°Cbefore an ovemight incubation on the section at
4°C. The next day, sections were washed in PBS and incubated in
biotinylated anti-rabbit IgG second antibody diluted 1:200 in PBS
containing 10% human serum for 30 min at room temperature.
Sections were washed in PBS and incubated for a further 1 h at
room temperature in Vectastain ABC reagent (Vector Labs).
Immunoproduct was visualized using 0.05% 3, 3-diaminobenzidine
and sections counterstained with Gill's haematoxylin.
Statistical analysis
We have previously studied the expression of FGF-2 mRNA in a
Tissue extraction panel of66breastcancertissues, using asemiquantitative RT-PCR
After histological confirmation of the diagnosis, a portion of the
tissue was pulverized to a fine powder, and cellular RNA was
extracted using the guanidium isothiocyanate procedure (Chirgwin
et al, 1979). For protein analysis the tissues were lysed in phos-
phate-buffered saline (PBS) containing 1% NP40, 0.1% sodium
dodecyl sulphate (SDS), 100 jig ml-' phenylmethylsulphonyl fluo-
ride (PMSF) and 5 jig ml- aprotinin and then mixed with an equal
volume ofSDS-PAGE samplebuffercontaining 2-mercaptoethanol.
SDS-PAGE and Western blotting
Aliquots oflysate containing 40 jg ofprotein wereelectrophoresed
through a 15% polyacrylamide gel. The separated proteins were
transferred onto nitrocellulose membranes for 3 h at 200 mA. The
blots were blocked with 3% milk powder in PBS containing 0.1%
Tween 20 (PBS-T) for 1 h, incubated with polyclonal rabbit anti-
FGF-2 antibody directed against amino acids 1-24 (a generous gift
from Dr A Baird) (Emoto et al, 1989) for 1 h and finally incubated
for a further hour with an anti-rabbit IgG antibody conjugated to
horseradish peroxidase (Sigma). After five washes with PBS-T,
bands were visualized using the enhanced chemoluminescence
(ECL) method (Amersham, UK). To ensure that approximately
the same number of epithelial cells were loaded in each lane, a
monoclonal antibody against the epithelial marker cytokeratin
18 (Sigma), followed by an anti-mouse-horseradish peroxidase
conjugate, was also used to probe the nitrocellulose membrane.
Immunohistochemistry
Breast tissue biopsies were immediately snap frozen in liquid
nitrogen. Tissue sections (8-10 jm) were cut and mounted on
coated slides. Immunostaining was performed using a three-stage
avidin-biotin complex (ABC) immunoperoxidase technique.
Briefly, frozen sections were fixed in 3.7% formaldehyde in PBS for
10 min and permeabilized in ice-cold acetone (50% followed by
Table 1 Details of patients studied
Characteristic Group la Per cent Group 2b
Total (n = 59) 51 8
Age
Range 29-79 42-66
Mean 57 56
Median 58 57
Menopausal status
Pre 14 29 1
Post 35 71 7
NK 2
Histological type
Invasive ductal carcinoma 34 67 8
Invasive lobular carcinoma 3 6 0
Other 15 27 0
Nodal status
Positive 17 33 5
Negative 34 67 2
Unknown 0 1
T stage
TO 1 2 0
Ti 13 27 3
T2 25 52 1
T3 6 13 3
T4 3 6
NK 3 1
ER status
Positive 18 62 3
Negative 11 38 2
NK 22 3
aThis group consisted of the patients who were followed up to assess the
prognostic significance of FGF-2 mRNA content. bThis group were patients
whose tumours were assessed for FGF-2 by Western blotting and
immunocytochemistry. NK, not known. ER, oestrogen receptor.
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Figure 1 Scattergram showing FGF-2 mRNA expression in non-malignant
and cancer tissues. A semiquantitative RT-PCR technique was used to
assess the amount of FGF-2 mRNA in non-malignant (N) and cancer (C)
tissues. Values are expressed as the ratio of FGF-2 and the ubiquitously
expressed glyceraldehyde phosphate dehydrogenase (GAP) RT-PCR
products (Luqmani et al, 1992). Mean values of 4.25 and 0.87 were found in
non-malignant and cancer tissues respectively, and there is a significant
difference between levels of FGF-2 mRNA expression in the two groups
(P < 0.0001)
method (Luqmani et al, 1992). The clinical progress of51 ofthese
patients has been followed for up to 10 years, and we are now in a
position to analyse the effect ofvariation in FGF-2 mRNA expres-
sion on disease-free and overall survival. Univariate survival
analyses were performed for overall and disease-free survival.
Cases were divided into high and low FGF-2 expressors using the
median value as the cut-offpoint. Survival curves were constructed
using the Kaplan-Meier method. Significance was calculated using
the log-rank test. In order to assess the effect ofother confounding
variables on survival, Cox's proportional hazards model was used
and included terms for FGF-2, T stage and nodal status.
RESULTS
Prognostic value of FGF-2 mRNA
We have previously studied the level ofFGF-2 mRNA in a panel of
human breast tumours (Luqmani et al, 1992). We found significantly
higher levels of FGF-2 mRNA in non-malignant breast tissues
(mean value 4.25) than in breast cancers (mean value 0.87) (Figure
1). Fifty-one patients from the original study have now been
followed up for a median time of 84 months. Details of these
Figure 2 Kaplan-Meier disease-free survival curves (A) and overall survival
curves (B) for patients with a high (>0.52) or low (<0.52) level of FGF-2
mRNA expression as assessed by semiquantitative RT-PCR analysis. The
solid lines show survival of patients with levels of FGF-2 mRNA lower than
the median. The dashed lines show the survival of patients with levels of
FGF-2 mRNA greater than orequal to the median
patients are shown in group 1 of Table 1. We are now able to
examine the possibility that FGF-2 mRNA couldprovide prognostic
information. Overall and disease-free survival analyses were
performed by dividing patients into two equal groups, using the
median value of FGF-2 mRNA expression as the cut-off point.
Kaplan-Meier survival plots show that higher levels of FGF-2
mRNA are associated with improved overall and disease-free
survival (Figure 2). Univariate log-rank analyses showed that these
differences were significant, giving P-values of 0.040 for overall
survival and 0.022 for disease-free survival. The effect of T stage
and nodal status on confounding variables was also tested using
Cox's proportional hazards model. In this analysis, FGF-2 remains a
significant predictor of good disease-free survival (P = 0.028),
although not ofoverall survival (P = 0.061). However, there was no
significant correlation between FGF-2 expression and oestrogen
receptor status.
Western blotting experiments on human breast tissues
Our previous results obtained using RT-PCR analysis had shown
generally lower amounts of FGF-2 mRNA in breast cancer than in
non-malignant breast tissues (Luqmani et al, 1992). We wished to
determine whether the level ofFGF-2 protein in malignant samples
was also generally lower than in non-malignant samples. We made
lysates of tissues and used Westem analysis to determine FGF-2
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Table 2 Immunocytochemical staining for FGF-2 in breast tissues
Tissue (histology) Degree of immunostaining in breast
epithelial cells
None + ++ +++
Infiltrating ductal carcinomaa 8 3 8 1
Infiltrating lobular carcinoma 3 0 0 0
DCIS 4 1 1 1
Normal breast tissue adjacent to
carcinoma or DCIS 0 0 0 15
aFive of these sections also showed staining of blood vessels.
Figure 3 Western blot analysis of FGF-2 expression in breast tissues. Cell
lysates were subjected to SDS-PAGE under reducing conditions and were
transferred to nitrocellulose membrane. Blots were blocked in 3% milk
powder and incubated sequentially with either a polyclonal anti-FGF-2
antibody or a monoclonal antibody against cytokeratin 18 and then with a
horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG
antibody. Bands were visualized by chemiluminescence. Lanes 1-2 and
5-8 contain malignant breast tissues; lanes 3 and 4 contain non-malignant
breast tissues
A
B
Figure 4 Immunohistochemical staining of cryostat sections. Frozen
sections of breast tissue were fixed in 3.7% formaldehyde, blocked with
goat serum and incubated with 0.5 jg ml-' anti-FGF-2. An avidin-biotin
complex immunoperoxidase method was used to locate FGF-2. A and B
both show sections of invasive breast cancer together with adjacent normal
ducts. Intense FGF-2 staining is present in the normal ducts of both
sections whereas reduced FGF-2 staining is present in the cancer cells
in A, and almost no FGF-2 is detectable in the cancer cells of B
(magnification x 200)
expression, using an antibody that we have previously shown to be
specific for FGF-2 (Gomm et al, 1991). Aliquots of lysate
containing 40 ,ug of protein were run in each lane, however the
cellular composition ofthe tissue samples may vary. Cytokeratin 18
is a marker ofbreast epithelial cells and is present in both malignant
and non-malignant breast epithelial cells (Levy et al, 1988). As a
control to monitor the epithelial cell content of the tissue samples,
we also probed using a monoclonal antibody against cytokeratin 18.
Details of the cancer tissues used are shown in group 2 in Table 1:
Results for a subgroup ofsix malignantbreast samples and two non-
malignant breast samples are shown in Figure 3. A range of FGF-2
expression levels was seen in malignant tissues, with some showing
equivalent levels of expression to non-malignant samples (lanes 5
and 7), whereas other samples contained lower amounts of FGF-2
(lanes 6 and 8); in addition, two ofthe malignant samples contained
no detectable FGF-2 (results not shown). There was generally a
decrease in the amount ofFGF-2 present in malignant samples with
several showing very low levels ofFGF-2, although some retained a
level similar to the non-malignant samples. FGF-2 (18 kDa) was
detectable in six ofthe malignant samples and was undetectable by
this method in a further two samples. Immunohistochemical
staining of these tissues gave consistent results with those samples
showing least FGF-2 expression in Western blotting experiments,
giving no FGF-2 immunohistochemical staining. The remaining
samples showed FGF-2 staining in malignant epithelial cells.
Immunohistochemistry of breast cancer sections
Frozen tissues from 15 cases of invasive carcinoma and one case
of ductal carcinoma in situ (DCIS) from the original RT-PCR
study were available for investigation by immunohistochemistry.
These samples and a further eight samples shown in group 2 of
Table 1 plus six additional DCIS tissues were investigated for
FGF-2 staining by immunohistochemistry. Previously, using
paraffin sections, we were unable to demonstrate the presence of
immunostainable FGF-2 in neoplastic breast epithelial cells
(Gomm et al, 1991). However, using a different protocol on frozen
sections, FGF-2 staining could be seen in cancer tissues as well as
non-malignant tissues. The primary antibody used has previously
been shown to be specific for FGF-2 (Gomm et al, 1991). The
results of staining are shown in Figure 4 and Table 2. Figure 4
demonstrates the reduction in FGF-2 expression in cancer using
two breast cancer sections that contain adjacent normal ducts. The
normal ducts of both sections show intense FGF-2 staining of
the nucleus and cytoplasm of both myoepithelial and epithelial
cells. The breast cancer cells show a much lower level of FGF-2
expression, with the section in Figure 4A having reduced levels of
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FGF-2 and the section in Figure 4B containing almost no FGF-2 in
the breast cancer cells. Controls using the same concentration of
rabbit IgG or anti-FGF-2 preincubated with FGF-2 were clear. In
ten sections of reduction mammoplasty tissue, similarly intense
staining ofboth myoepithelial and epithelial cells was seen (results
not shown). In the tumour samples studied, FGF-2 staining was
generally lighter. Tumour cells in all three invasive lobular carci-
noma examined were negative. In invasive ductal carcinoma, eight
cases were negative, while the remaining 12 cases showed hetero-
geneous and mostly weak or moderate staining (+, ++), with the
exception ofone case in which the degree ofnuclear staining in the
neoplastic cells was equal in intensity to that seen in the normal
epithelial component (Table 2). DCIS also showed a variable
staining result, with four cases totally negative and three showing
variable degrees ofpositivity. The myoepithelial cells remaining in
DCIS sections showed intense FGF-2 staining.
A comparison ofresults achieved by RT-PCR and immunohis-
tochemistry on these tissues showed a high degree of correlation,
with higher levels of FGF-2 mRNA generally leading to higher
FGF-2 expression. Four samples showed levels of FGF-2 mRNA
in excess of the median (0.52), and three of these showed signifi-
cant immunostaining (++,+++) for FGF-2 in the neoplastic breast
epithelial cells. Eleven cases showed FGF-2 mRNA levels beneath
the median and nine ofthese showed either absent (-) or very weak
(+) immunostaining ofa few cells.
DISCUSSION
Our results show that FGF-2 is present in malignant breast epithe-
lial cells, but to a lesser extent than that observed in normal breast
epithelial cells. Thus, immunohistochemistry demonstrated greater
FGF-2 staining intensity in the 15 cases in which normal tissue
was present. These results parallel our observations of FGF-2
mRNA (Luqmani et al, 1992) in which we reported lower levels of
FGF-2 mRNA in breast carcinoma extracts than in extracts of
normal breast tissue. The observed decrease in FGF-2 expression
in breast cancers may partly be due to the loss of myoepithelial
cells that occurs in malignant disease. However, our immunohisto-
chemical analysis shows that the level of FGF-2 staining in
luminal epithelial cells also decreases. This decrease in expression
is seen quite early in disease, with DCIS sections showing this
effect as well as invasive cancers. Statistical analysis of FGF-2
expression levels on tumour samples studied by semiquantitative
RT-PCR analysis and immunohistochemistry also indicate that
breast carcinomas synthesizing FGF-2 are less aggressive than
those that do not. This is reflected in increased disease-free and
overall survival for tumours expressing higher levels ofFGF-2.
This is, to our knowledge, the first report showing immunohisto-
chemical staining for FGF-2 in human breast luminal epithelial
cells. Ourimmunohistochemistry results using frozen sections gave
a different staining pattem from that in previously published work
using paraffin sections (Gomm et al, 1991). Whereas previously
FGF-2 had been found in myoepithelial cells, frozen sections
clearly show expression in luminal epithelial cells as well. The
presence of FGF-2 in epithelial cells is confirmed by other studies
in which mRNA encoding FGF-2 and FGF-2 protein have been
found in human breast epithelial cell lines (Li and Shipley, 1991;
Ke et al, 1993; Penault-Llorca et al, 1995). The effect of different
fixation protocols on the location of FGF-2 staining has been well
documented (Healy et al, 1992; Ishigooka et al, 1992). In our
hands, FGF-2 staining in epithelial cells is easily lost when tissues
are embedded in paraffin or subjected to organic solvent fixation.
For instance, the use of acetone rather than formaldehyde fixation
on frozen sections led to a loss ofFGF-2 staining in epithelial cells
but not in myoepithelial cells or basement membrane. Binding of
FGF-2 to proteoglycans is known to stabilize the growth factor, and
it is possible that the binding ofFGF-2 to the basement membrane
and proteoglycans on the surface of myoepithelial cells results in
the relative stability ofFGF-2 staining at these positions.
The role ofFGF-2 in breast carcinoma cells is unclear, as is the
significance of its down-regulation. In the normal breast, much of
the FGF-2 appears to derive from the myoepithelial cells not only
in humans (Ke et al, 1993), but also in rat (Barraclough et al, 1990)
and mouse (Coleman-Krnacik and Rosen, 1994). It may play some
role as a survival factor; our results indicate that FGF-2 promotes
survival of breast epithelial cells in vitro (JJ Gomm et al, unpub-
lished results). Carcinoma cells may have lost their dependence on
FGF-2 for survival. Cell proliferation experiments suggest that
FGF-2 has only a slight stimulatory effect on the growth ofbreast
cancer cell lines (Valverius et al, 1990; Smith et al, 1994; Johnston
et al, 1995). Others have found inhibition of breast cancer cell
growth by FGF-2 (McLeskey et al, 1994). This may suggest that
FGF-2 has a role in maintaining the differentiated state ofthe duct
rather than promoting cell proliferation. This is consistent with the
high levels of FGF-2 that we have shown to be present in the
normal breast. Ifthis is the case, then loss ofFGF-2 might lead to
more aggressive tumours and the decreased disease-free and total
survival seen in this study.
Alternatively, loss of FGF-2 expression may not be causal in
increasing the malignancy of breast cancer cells but may be a
marker of less differentiated cancers. Breast cancer cells which
have lost epithelial markers have been shown to be more invasive,
and this could result in decreased disease-free survival (Thompson
et al, 1992).
Measurement of FGF-2 expression in breast cancer may have
some role as a prognostic indicator as, in our small series, we
found that breast carcinomas with high FGF-2 levels have a better
outcome than those that have low levels. However, these prelimi-
nary results need confirming in a larger series. We will compare
the level of FGF-2 expression with that of other putative prog-
nostic parameters, including oestrogen and progesterone receptor,
c-erbB-2 and EGF receptor (Gullick, 1990; Nicholson, 1990), and
correlate this with response to endocrine and cytotoxic therapy.
ABBREVIATIONS
FGF, fibroblast growth factor; FGFR, fibroblast growth factor
receptor; RT-PCR, reverse transcriptase-polymerase chain reac-
tion; DCIS, ductal carcinoma in situ.
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